Globus Medical (NYSE:GMED) Given New $80.00 Price Target at Stifel Nicolaus

Globus Medical (NYSE:GMED) had its price target trimmed by Stifel Nicolaus from $95.00 to $80.00 in a research report report published on Wednesday, Marketbeat.com reports. The brokerage currently has a hold rating on the medical device company’s stock.

GMED has been the subject of several other research reports. Royal Bank Of Canada boosted their price objective on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Wells Fargo & Company cut their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Piper Sandler cut their target price on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. Finally, Needham & Company LLC raised their price objective on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $105.42.

Globus Medical Stock Performance

Shares of GMED stock opened at $76.23 on Wednesday. The stock’s 50-day simple moving average is $81.13 and its 200-day simple moving average is $86.97. The firm has a market capitalization of $10.35 billion, a PE ratio of 17.73, a P/E/G ratio of 1.63 and a beta of 0.95. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period last year, the business posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Sell-side analysts forecast that Globus Medical will post 4.74 earnings per share for the current year.

Insider Transactions at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Several hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC lifted its holdings in Globus Medical by 2.3% in the first quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after acquiring an additional 151 shares during the last quarter. SBI Securities Co. Ltd. lifted its position in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares during the last quarter. Parallel Advisors LLC boosted its stake in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares during the period. Finally, Allworth Financial LP increased its position in shares of Globus Medical by 1.6% during the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock valued at $1,095,000 after acquiring an additional 199 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.